APLS
Apellis Pharmaceuticals, Inc.
$41.03
+0.00 (+0.00%)
At close · May 15
Market Cap
$5.25B
Shares
128,021,277
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$41.03
Open$41.03
Day$41.03–41.03
52W$16.10–41.14
Avg vol 30d4.1M
Short int10.8M · 8.4% float · 3.1d
Short vol51%
Last earningsJan 12, 2026
DataJan 2020–May 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+57% above
+
Price vs 50-day avg
+24% above
−
RSI (14)
84 · overbought
−
MACD trend
negative
+
52-week position
100% · near high
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $33 › 200d $26 — 50d above 200d
+
Institutional flow
+15% holders QoQ · +124 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
8.40% of float · ▼ -24.5% MoM · 3.1 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
326 holders — near 3-yr high, broad support
Fundamentals
Excellent
+
Revenue growth
+28% Y/Y
+
EPS growth
+113% Y/Y
+
Free cash flow
$45.0M
−
Valuation
P/E 37.6 · rich
+
Balance sheet
net cash $373.2M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+57% above
Bullish
Price vs 50-day avg
+24% above
Bullish
RSI (14)
84 · overbought
Bearish
MACD trend
negative
Bearish
52-week position
100% · near high
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $33 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
+15% holders QoQ · +124 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.40% of float · ▼ -24.5% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
326 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $16
Now $41 · 100%
52-wk high $41
vs 200-day avg +57%
vs 50-day avg +24%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| EMPAVELI payer coverage to label or with minimal restrictions | 95% | Full year 2025 | — |
| SYFOVRE total market share | 60% | Q4 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APLS
this stock
Apellis Pharmaceuticals, Inc.
|
$5.25B | +63.3% | +28.5% | 37.6 | 8.4% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APLS | +0.0% | +0.3% | +110.0% | +0.2% | +63.3% |
| SPY | +0.4% | +4.3% | +13.5% | +3.1% | +8.6% |
| vs SPY | -0.4% | -3.9% | +96.5% | -2.9% | +54.8% |